Alkermes flops FDA’s ‘remote review’ at manufacturing site for schizophrenia, bipolar disorder drug
The COVID-19 pandemic has changed the way the pharmaceutical industry works, crucially in how regulators inspect key manufacturing sites. To skirt around lockdowns, the FDA...